Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center

The National Institute of Mental Health (NIMH), a constituent institute of the United States Department of Health and Human Services (HHS), has released a forecast for a single-source cooperative agreement funding opportunity titled “Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center.” This opportunity aligns with the broader federal effort to accelerate medical innovations and improve outcomes for individuals at clinical high risk for psychosis through the AMP SCZ program. The primary objective of this funding opportunity is to renew support for the AMP SCZ Clinical Trial Data Processing, Analysis, and Coordination Center. This center plays a crucial role in managing, directing, and coordinating the data-related activities of the broader AMP SCZ Clinical Trial Network, originally funded under RFA-MH-24-150. These responsibilities include the collection, processing, and multi-modal analysis of digital and biomarker data to inform the efficacy of pharmacological interventions. The center must also collaborate with clinical research organizations to ensure proper study conduct and data handling across multiple sites. The funding instrument will be a cooperative agreement utilizing the U24 activity code, indicating substantial involvement by NIH staff in the project’s activities and oversight. The total estimated program funding is $12,000,000, with one award anticipated. While the specific award ceiling and floor are not provided in the forecast, it is clear that this is a significant investment into data infrastructure and operational coordination for psychosis prevention research. Eligibility for this opportunity includes a wide range of entities such as public and state-controlled institutions of higher education, nonprofit organizations, for-profit organizations (including small businesses), tribal governments and organizations, state and local governments, and public housing authorities. Notably, Brigham and Women’s Hospital, as an awardee under RFA-MH-24-151, is highlighted as a likely applicant due to its expertise in clinical coordination and bioinformatics relevant to psychosis research. As a forecasted opportunity, applications are not being accepted at this time. The estimated posting date is September 24, 2025, with an application due date of October 24, 2025. The estimated award and project start date is July 1, 2026. Given the program’s role within a larger strategic research initiative, interested parties are advised to begin internal preparations and consider partnerships that enhance data analysis and trial coordination capacities. For questions or further details, interested parties may contact Dr. Suzanne Garcia at the National Institute of Mental Health via phone at 202-345-1260 or by email at suzanne.garcia@nih.gov. This early notice allows potential applicants ample time to prepare competitive proposals that meet the complex requirements of the AMP SCZ initiative.